Home
University of Bergen
Jørgen Valeur's picture

Jørgen Valeur

Guest Researcher
Department of Clinical Science
  • E-mailjorgen.valeur@uib.no
  • Visitor Address
    Haukeland universitetssykehus, Laboratoriebygget
    5009 Bergen
  • Postal Address
    Postboks 7804
    5020 Bergen
Academic article
  • Show author(s) (2023). Increased plasma levels of non-sugar sweeteners in patients with symptomatic carotid atherosclerosis. Scandinavian Cardiovascular Journal.
  • Show author(s) (2023). Effects of a low FODMAP diet on gut microbiota in individuals with treated celiac disease having persistent gastrointestinal symptoms-a randomized controlled trial. British Journal of Nutrition.
  • Show author(s) (2022). Vitamin D in Alzheimer's Disease: Low Levels in Cerebrospinal Fluid Despite Normal Amounts in Serum. Journal of Alzheimer's Disease. 1301-1314.
  • Show author(s) (2022). Fecal level of butyric acid, a microbiome-derived metabolite, is increased in patients with severe carotid atherosclerosis. Scientific Reports. 1-9.
  • Show author(s) (2022). Associations Between Intrathecal Levels of Vitamin D, Cytokines, and Core Biomarkers of Alzheimer's Disease: A Cross-Sectional Study. Journal of Alzheimer's Disease. 825-834.
  • Show author(s) (2021). Responses to faecal microbiota transplantation in female and male patients with irritable bowel syndrome. World Journal of Gastroenterology (WJG). 2219-2237.
  • Show author(s) (2021). Mortality and microbial diversity after allogenic hematopoietic stem cell transplantation: secondary analysis of a randomized nutritional intervention trial. Scientific Reports.
  • Show author(s) (2021). Long-term effects of fecal microbiota transplantation (FMT) in patients with irritable bowel syndrome. Neurogastroenterology and Motility.
  • Show author(s) (2020). Study protocol of the Bergen brain-gut-microbiota-axis study: A prospective case-report characterization and dietary intervention study to evaluate the effects of microbiota alterations on cognition and anatomical and functional brain connectivity in patients with irritable bowel syndrome. Medicine. 1-8.
  • Show author(s) (2020). Prebiotic effect of inulin-type fructans on faecal microbiota and short-chain fatty acids in type 2 diabetes: a randomised controlled trial. European Journal of Nutrition. 3325-3338.
  • Show author(s) (2020). Postprandial symptoms in patients with functional dyspepsia and irritable bowel syndrome: relations to ultrasound measurements and psychological factors. Journal of Neurogastroenterology and Motility. 96-105.
  • Show author(s) (2020). Fecal Microbiota Transplantation in Systemic Sclerosis: A Double-Blind, Placebo-Controlled Randomized Pilot Trial. PLOS ONE. 1-14.
  • Show author(s) (2020). Changes in fecal short-chain fatty acids following fecal microbiota transplantation in patients with irritable bowel syndrome. Neurogastroenterology and Motility.
  • Show author(s) (2020). Changes in Faecal Short-Chain Fatty Acids after Weight-Loss Interventions in Subjects with Morbid Obesity. Nutrients. 12 pages.
  • Show author(s) (2019). Plasma cytokine levels in patients with chronic alcohol overconsumption: relations to gut microbiota markers and clinical correlates. Alcohol. 35-40.
  • Show author(s) (2019). Effects of a Cod Protein Hydrolysate Supplement on Symptoms, Gut Integrity Markers and Fecal Fermentation in Patients with Irritable Bowel Syndrome. Nutrients. 1-13.
  • Show author(s) (2019). Clinical response to fecal microbiota transplantation in patients with diarrhea-predominant irritable bowel syndrome is associated with normalization of fecal microbiota composition and short-chain fatty acid levels. Scandinavian Journal of Gastroenterology. 690-699.
  • Show author(s) (2019). Characterization of gut microbiota composition and functions in patients with chronic alcohol overconsumption. Gut microbes. 663-675.
  • Show author(s) (2019). Attention deficit and hyperactivity disorder symptoms respond to gluten-free diet in patients with coeliac disease. Scandinavian Journal of Gastroenterology. 571-576.
  • Show author(s) (2019). Are Nonnutritive Sweeteners Obesogenic? Associations between Diet, Faecal Microbiota, and Short-Chain Fatty Acids in Morbidly Obese Subjects. Journal of Obesity. 1-8.
  • Show author(s) (2018). Severe, reversible dysphagia and malnutrition in a patient with tumour-induced hypophosphataemia. BMJ Case Reports.
  • Show author(s) (2018). Separating “good” from “bad” faecal dysbiosis – evidence from two cross-sectional studies. BMC Obesity. 1-10.
  • Show author(s) (2018). Preterm infants have distinct microbiomes not explained by mode of delivery, breastfeeding duration or antibiotic exposure. International Journal of Epidemiology. 1658-1669.
  • Show author(s) (2018). Okklusjon av Percherons arterie. Tidsskrift for Den norske legeforening. 1854-1854.
  • Show author(s) (2018). Impact of HIV and type 2 diabetes on gut microbiota diversity, tryptophan catabolism and endothelial dysfunction. Scientific Reports. 9 pages.
  • Show author(s) (2018). Fecal microbiota transplantation for primary Clostridium difficile infection. New England Journal of Medicine. 2535-2537.
  • Show author(s) (2018). Faecal microbial markers and psychobiological disorders in subjects with morbid obesity. A cross-sectional study. Behavioral Sciences. 12 pages.
  • Show author(s) (2018). Exploring gut microbiota composition as an indicator of clinical response to dietary FODMAP restriction in patients with irritable bowel syndrome. Digestive Diseases and Sciences. 429-436.
  • Show author(s) (2018). Evaluation of a faecal dysbiosis test for irritable bowel syndrome in subjects with and without obesity. Scandinavian Journal of Clinical and Laboratory Investigation. 109-113.
  • Show author(s) (2017). Persistent symptoms in patients with Crohn’s disease in remission: An exploratory study on the role of diet. Scandinavian Journal of Gastroenterology. 573-578.
  • Show author(s) (2017). Johan Karl Unger Vetlesen – Noregs fyrste gastroenterolog. Michael. 217-230.
  • Show author(s) (2017). Effects of varying dietary content of fermentable short-chain carbohydrates on symptoms, fecal microenvironment, and cytokine profiles in patients with irritable bowel syndrome. Neurogastroenterology and Motility. 1-9.
  • Show author(s) (2017). Chronic alcohol overconsumption may alter gut microbial metabolism: a retrospective study of 719 13C-D-xylose breath test results. Microbial Ecology in Health and Disease.
  • Show author(s) (2016). Systemic symptoms in irritable bowel syndrome: An investigative study on the role of enterocyte disintegrity, endotoxemia and inflammation. Molecular Medicine Reports. 5072-5076.
  • Show author(s) (2016). Fecal Fermentation in Irritable Bowel Syndrome: Influence of Dietary Restriction of Fermentable Oligosaccharides, Disaccharides, Monosaccharides and Polyols. Digestion. 50-56.
  • Show author(s) (2016). Extra-intestinal symptoms in patients with irritable bowel syndrome: related to high total IgE levels and atopic sensitization? Scandinavian Journal of Gastroenterology. 908-913.
  • Show author(s) (2016). En metadonbruker med anemi, skjelettsmerter og endret utseende. Tidsskrift for Den norske legeforening. 925-929.
  • Show author(s) (2015). The effect of body position on postprandial perceptions, gastric emptying, and intragastric meal distribution: An ultrasonographic study in reclining healthy subjects. Scandinavian Journal of Gastroenterology. 170-173.
  • Show author(s) (2015). Oatmeal porridge: Impact on microflora-associated characteristics in healthy subjects. British Journal of Nutrition. 62-67.
  • Show author(s) (2015). Low serum levels of short-chain fatty acids after lactulose ingestion may indicate impaired colonic fermentation in patients with irritable bowel syndrome. Clinical and Experimental Gastroenterology. 303-308.
  • Show author(s) (2014). Abnormal accumulation of intestinal fluid following ingestion of an unabsorbable carbohydrate in patients with irritable bowel syndrome: an MRI study. Neurogastroenterology and Motility. 1686-1693.
  • Show author(s) (2013). Chronic fatigue in patients with unexplained self-reported food hypersensitivity and irritable bowel syndrome: validation of a Norwegian translation of the Fatigue Impact Scale. Clinical and Experimental Gastroenterology. 101-107.
  • Show author(s) (2012). Functional bowel symptoms, fibromyalgia and fatigue: A food-induced triad? Scandinavian Journal of Gastroenterology. 914-919.
  • Show author(s) (2011). Subjective food hypersensitivity: assessment of enterochromaffin cell markers in blood and gut lavage fluid. International Journal of General Medicine. 555-560.
  • Show author(s) (2010). Job stress and coping strategies in patients with subjective food hypersensitivity. Scandinavian Journal of Psychology. 179-184.
  • Show author(s) (2010). Intestinal fermentation in patients with self-reported food hypersensitivity: painful, but protective? Clinical and Experimental Gastroenterology. 65-70.
  • Show author(s) (2010). Intestinal B cell-activating factor: an indicator of non-IgE mediated hypersensitivity reactions to food? Alimentary Pharmacology and Therapeutics. 66-73.
  • Show author(s) (2010). Indications of 'atopic bowel' in patients with self-reported food hypersensitivity. Alimentary Pharmacology and Therapeutics. 1112-1122.
  • Show author(s) (2010). Duodenal administered seal oil for patients with subjective food hypersensitivity: an explorative open pilot study. International Journal of General Medicine. 383-392.
  • Show author(s) (2010). Do psychological factors predict symptom severity in patients with subjective food hypersensitivity? Scandinavian Journal of Gastroenterology. 835-843.
  • Show author(s) (2009). Subjective health complaints and quality of life in patients with irritable bowel syndrome following Giardia lamblia infection: A case control study. Scandinavian Journal of Gastroenterology. 308-313.
  • Show author(s) (2009). Helseeffekter av probiotika - en kritisk vurdering. Norsk tidsskrift for ernæring (NTFE). 22-26.
  • Show author(s) (2009). Food allergy alters jejunal circular muscle contractility and induces local inflammatory cytokine expression in a mouse model. BMC Gastroenterology.
  • Show author(s) (2009). Carbohydrate intolerance in patients with self-reported food hypersensitivity: Comparison of lactulose and glucose. Scandinavian Journal of Gastroenterology. 1416-1423.
  • Show author(s) (2009). Antibiotic or bacterial therapy in post-giardiasis irritable bowel syndrome. Scandinavian Journal of Gastroenterology. 1296-1303.
  • Show author(s) (2008). Plasma glucagon-like peptide 1 and peptide YY levels are not altered in symptomatic fructose-sorbitol malabsorption. Scandinavian Journal of Gastroenterology. 1212-1218.
  • Show author(s) (2008). Laktosemalabsorbsjon - en fordel? Norsk tidsskrift for ernæring (NTFE). 10-13.
Academic lecture
  • Show author(s) (2023). Kosthold og ernæringsstatus ved nydiagostisert IBD: resultater fra IBSEN III.
  • Show author(s) (2023). Epidemiologi og patofysiologi ved diabetisk diaré (DIAREPA).
  • Show author(s) (2021). Kort- og langtidseffekten av lav FODMAP-dietten på symptomer og kortkjedede fettsyrer hos pasienter med irritabel tarmsyndrom.
  • Show author(s) (2021). Increased fecal levels of the SCFA butyrate may indicate poor absorption due to disrupted gut barrier in patients with carotid stenosis.
  • Show author(s) (2021). Effects of low-FODMAP diet on gut microbiota in individuals with treated celiac disease having persistent gastrointestinal symptoms.
  • Show author(s) (2020). Short and extended effects of a low FODMAP diet on symptoms and short-chained fatty acids in patients with irritable bowel syndrome.
  • Show author(s) (2020). Long-term effects of faecal microbiota transplantation (FMT) in patients with irritable bowel syndrome.
  • Show author(s) (2019). Kognitive symptomer hos pasienter med cøliaki før og etter glutenfri kost.
  • Show author(s) (2019). Effect of faecal microbiota transplantation on gut microenvironment and symptoms in patients with irritable bowel syndrome.
  • Show author(s) (2019). Are non-nutritive sweeteners obesogenic by altering the faecal microbiota and their metabolites?
  • Show author(s) (2018). Vedvarende symptomer hos pasienter med Crohns sykdom i remisjon: Har kostholdet betydning?
  • Show author(s) (2018). Tarmfloraendringer hos pasienter med forhøyet alkoholkonsum.
  • Show author(s) (2018). Fecal microbiota transplantation versus antibiotics for primary Clostridium difficile infection - a multicenter, randomized proof-of-concept trial.
  • Show author(s) (2018). Fecal microbiota transplant in primary Clostridium difficile infection - a proof-of-concept trial.
  • Show author(s) (2018). Ernæringsstatus hos personer med høyt alkoholinntak.
  • Show author(s) (2017). Microbial DNA markers associated with response to a low FODMAP diet in patients with irritable bowel syndrome.
  • Show author(s) (2017). Analyse og funksjon av kortkjedede fettsyrer (Short-Chain Fatty Acids; SCFA).
  • Show author(s) (2017). "Neurasthenia gastrica" revisited: The gut in Norwegian neurasthenia 1880-1930.
  • Show author(s) (2016). Påvirker alkohol tarmens mikroflora? En retrospektiv studie av 719 13C-D-Xylose pusteprøver.
  • Show author(s) (2016). Mikrobiota og fermentering i tarm.
  • Show author(s) (2016). Low FODMAP diet alters symptoms, microbiota, short-chain fatty acids and cytokine profiles in patients with IBS: A randomized controlled trial.
  • Show author(s) (2016). Low FODMAP diet alters symptoms, microbiota, short-chain fatty acids and cytokine profiles in patients with IBS: A randomized controlled trial.
  • Show author(s) (2016). IBS och kost.
  • Show author(s) (2016). Avføring som terapi.
  • Show author(s) (2015). Diet and irritable bowel syndrome: a microbial perspective.
  • Show author(s) (2015). "Alcoholic Bowel Syndrome" (ABS).
  • Show author(s) (2014). FODMAP-intoleranse ved IBS: En MRI-studie.
  • Show author(s) (2013). FODMAP-intolerance in IBS: Visualization by Magnetic Resonance Imaging.
  • Show author(s) (2012). Matoverfølsomhet ved irritabel tarm.
  • Show author(s) (2012). Irritabel tarm-syndrom: Er det karbohydratintoleranse?
  • Show author(s) (2012). Funksjonelle mage-tarm-lidelser.
  • Show author(s) (2012). Fibromyalgi og kronisk tretthetssyndrom hos pasienter med matoverfølsomhet.
  • Show author(s) (2010). Tykktarmens funksjon.
  • Show author(s) (2010). IBS: En forstyrrelse i tykktarmens funksjon.
  • Show author(s) (2009). Karbohydratintoleranse ved IBS.
  • Show author(s) (2009). Irritable bowel syndrome - an enterometabolic disorder?
  • Show author(s) (2009). Ingestion of lactulose replicates habitual symptoms in patients with irritable bowel syndrome.
  • Show author(s) (2009). Indications of `atopic bowel` in patients with irritable bowel syndrome (IBS).
  • Show author(s) (2009). Colonic contents, particularly various gases and short-chain fatty acids, play an important role in the generation of IBS symptoms and could be useful therapeutic targets.
  • Show author(s) (2009). A role for chromogranin A in functional gastrointestinal disorders?
  • Show author(s) (2007). Ileal bremsefunksjon ved fruktoseintoleranse.
  • Show author(s) (2006). Sult og metthet - om den biologiske reguleringen av fødeinntaket.
Feature article
  • Show author(s) (2023). Tarmflora og tarmsykdom - en edruelig formaning. Tidsskrift for Den norske legeforening. 849-850.
  • Show author(s) (2019). Snille bakterier finnes ikke. Tidsskrift for Den norske legeforening. 504-505.
  • Show author(s) (2015). Beskyttende bakterier. Nationen.
  • Show author(s) (2013). Irritabel tarm-syndrom - et mikrobielt perspektiv. Tidsskrift for Den norske legeforening. 2276-2278.
  • Show author(s) (2009). Napoleons mage. Tidsskrift for Den norske legeforening. 122-123.
  • Show author(s) (2008). Hvorfor har vi tykktarm? Tidsskrift for Den norske legeforening. 1298-1300.
  • Show author(s) (2007). Sult og metthet - en biologisk forklaringsmodell. Tidsskrift for Den norske legeforening. 46-48.
Abstract
  • Show author(s) (2023). Gut microbiota at diagnosis is associated with clinical features and future disease course in Inflammatory Bowel Disease: Data from IBSEN III, a new large Norwegian population-based inception cohort. Journal of Crohn's and Colitis. i1028-I2029.
  • Show author(s) (2022). Bergen Braingut Study: Relations between fecal microbiota profile and its metabolites (short-chain fatty acids) and symptoms in irritable bowel syndrome. United European Gastroenterology journal. 412-412.
  • Show author(s) (2021). Responses to faecal microbiota transplantation in female and male patients with irritable bowel syndrome. United European Gastroenterology journal. 635-636.
  • Show author(s) (2020). Long-term effects of faecal microbiota transplantation (FMT) in patients with irritable bowel syndrome. United European Gastroenterology journal. 46-46.
  • Show author(s) (2020). Changes in fecal short-chain fatty acids (SCFA) following fecal microbiota transplantation (FMT) in patients with irritable bowel syndrome (IBS). Neurogastroenterology and Motility.
  • Show author(s) (2018). Psychological factors in patients with functional gastrointestinal disorders: relation to dyspeptic symptoms and gastric dysmotility as measured with ultrasound. United European Gastroenterology journal. A506-A506.
  • Show author(s) (2018). Nausea in patients with IBS and functional dyspepsia. Neurogastroenterology and Motility. 126-126.
  • Show author(s) (2018). Effects of faecal microbiota transplantation on gut microenvironment and symptoms in patients with irritable bowel syndrome. Neurogastroenterology and Motility. 178-179.
  • Show author(s) (2018). Cognitive impairment in coeliac disease: normalization following gluten-free diet. United European Gastroenterology journal. A330-A330.
  • Show author(s) (2017). Microbial DNA markers associated with response to a low FODMAP diet in patients with irritable bowel syndrome. Gastroenterology. S-44-S-45.
  • Show author(s) (2017). Functional food for functional disorders. Microbial Ecology in Health and Disease.
  • Show author(s) (2017). Effect of faecal microbiota transplantation on gut bacterial fermentation products in patients with irritable bowel syndrome. United European Gastroenterology journal. A563-A564.
  • Show author(s) (2017). Avføring som terapi. Årbok / Det norske videnskaps-akademi. 450-451.
  • Show author(s) (2017). Alterations of gut microbiota composition in patients with chronic alcohol overconsumption. Neurogastroenterology and Motility. 84-85.
  • Show author(s) (2016). Low FODMAP diet alters symptoms, microbiota, short-chain fatty acids and cytokine profiles in patients with IBS: A randomized controlled trial. United European Gastroenterology journal. A101-A101.
  • Show author(s) (2016). High levels of serum total IgE-antibodies are not related to intestinal and extra-intestinal symptom severity in irritable bowel syndrome. Neurogastroenterology and Motility. 63-63.
  • Show author(s) (2016). Dietary FODMAP restriction alters faecal fermentation in patients with IBS. Neurogastroenterology and Motility. 25-25.
  • Show author(s) (2015). Markers of intestinal injury and endotoxemia in patients with irritable bowel syndrome. Neurogastroenterology and Motility. 105-105.
  • Show author(s) (2015). Det første nasjonale møtet om funksjonelle mage-tarm-lidelser (FGID) 18. mars 2015. NGF-nytt. 32-33.
  • Show author(s) (2014). Low serum levels of short-chain fatty acids after lactulose ingestion may indicate impaired microbial fermentation in patients with irritable bowel syndrome. United European Gastroenterology journal. A556-A556.
  • Show author(s) (2014). Influence of a low-FODMAP diet on symptoms and gut microbiota in patients with irritable bowel syndrome. United European Gastroenterology journal. A556-A556.
  • Show author(s) (2013). FODMAP-intolerance in IBS: Visualization by Magnetic Resonance Imaging. United European Gastroenterology journal. A110-A110.
  • Show author(s) (2012). Comorbidity in patients with perceived food hypersensitivity. Gut. A337.
  • Show author(s) (2010). Unexplained, self-reported food hypersensitivity: A fermentation problem? Neurogastroenterology and Motility. 79-80.
  • Show author(s) (2009). Symptoms and rectal fermentation products in response to lactulose challenge in patients with irritable bowel syndrome. Neurogastroenterology and Motility. 83-83.
  • Show author(s) (2009). Potential role of B-cell activating factor in non-IgE-mediated hypersensitivity reactions to food. Gut. A116-A116.
  • Show author(s) (2009). Irritable bowel syndrome - an enterometabolic disorder? Scandinavian Journal of Gastroenterology. 28-28.
  • Show author(s) (2009). Indications of `atopic bowel` in patients with irritable bowel syndrome (IBS). Neurogastroenterology and Motility. 7-7.
  • Show author(s) (2009). Indications of "atopic bowel" in patients with irritable bowel syndrome. Gut. A20-A20.
  • Show author(s) (2008). Neuroendocrine biomarkers of symptomatic carbohydrate malabsorption. Neurogastroenterology and Motility. 138-138.
  • Show author(s) (2008). Jejunal dysmotility in food allergy mouse model. Scandinavian Journal of Gastroenterology. 32-32.
  • Show author(s) (2008). Jejunal dysmotility in a food allergy mouse model. Neurogastroenterology and Motility. 45-45.
Academic literature review
  • Show author(s) (2023). Short-chain fatty acids as a link between diet and cardiometabolic risk: a narrative review. Lipids in Health and Disease.
  • Show author(s) (2023). Diet-microbiota interaction in irritable bowel syndrome: looking beyond the low-FODMAP approach. Scandinavian Journal of Gastroenterology.
  • Show author(s) (2017). Microbial trimethylamine-N-oxide as a disease marker: something fishy? Microbial Ecology in Health and Disease.
  • Show author(s) (2016). Probiotic lactic acid bacteria - the fledgling cuckoos of the gut? Microbial Ecology in Health and Disease.
  • Show author(s) (2015). Indole - the scent of a healthy "inner soil". Microbial Ecology in Health and Disease.
  • Show author(s) (2014). Tryptophan: ‘essential’ for the pathogenesis of irritable bowel syndrome? Scandinavian Journal of Gastroenterology. 1493-1498.
  • Show author(s) (2011). Perceived food hypersensitivity: A review of 10 years of interdisciplinary research at a reference center. Scandinavian Journal of Gastroenterology. 1169-1178.
  • Show author(s) (2011). Pasienten tåler ikke mat - hva skal vi tro? Utposten. 36-40.
  • Show author(s) (2011). Matoverfølsomhet- Et paradigmeskifte? Fagbladet Allergi i praksis. 30-33.
  • Show author(s) (2010). Kan tarmbakteriene gjøre oss fete? Norsk tidsskrift for ernæring (NTFE). 12-14-16-17.
  • Show author(s) (2010). Bør personer med irritabel tarm spise mindre tungt fordøyelige karbohydrater? Norsk tidsskrift for ernæring (NTFE). 12-17.
Article in business/trade/industry journal
  • Show author(s) (2023). Vampyrmage. NGF-nytt. 34-35.
  • Show author(s) (2023). Strutsens stålmage. NGF-nytt. 54-54.
  • Show author(s) (2022). Urtarmdyret. NGF-nytt. 42-42.
  • Show author(s) (2022). Maur i magen. NGF-nytt. 38-39.
  • Show author(s) (2022). Firkantmysteriet. NGF-nytt. 58-58.
  • Show author(s) (2022). Engastrasjon. NGF-nytt. 38-38.
  • Show author(s) (2021). Middelaldersk magetømmingstest. NGF-nytt. 48-48.
  • Show author(s) (2021). Gastroptose. NGF-nytt. 20-22.
  • Show author(s) (2021). Frosk i magen. NGF-nytt. 45-45.
  • Show author(s) (2021). Dovendyrets dobesøk. NGF-nytt. 34-34.
  • Show author(s) (2020). Will it float? NGF-nytt. 35-35.
  • Show author(s) (2020). Spiraltarm. NGF-nytt. 44-44.
  • Show author(s) (2020). Paris' mage. NGF-nytt. 28-28.
  • Show author(s) (2020). Den mekaniske and. NGF-nytt. 31-31.
  • Show author(s) (2019). Toalett i særklasse. NGF-nytt. 37-37.
  • Show author(s) (2019). Tarmflorabehandling. Tidsskrift for Den norske legeforening. 859-859.
  • Show author(s) (2019). Strupesekk. NGF-nytt. 32-32.
  • Show author(s) (2019). Honningmage. NGF-nytt. 30-30.
  • Show author(s) (2018). Surmaget. NGF-nytt. 42-42.
  • Show author(s) (2018). Mynter i magen. NGF-nytt. 26-26.
  • Show author(s) (2018). I hvalens mage. NGF-nytt. 25-25.
  • Show author(s) (2018). Fordøyelse til besvær. Helsesekretæren. 11-13.
  • Show author(s) (2018). Fedmeepidemien - ligger svaret i tarmen? Indremedisineren. 22-25.
  • Show author(s) (2018). Eksklusive ekskrementer. NGF-nytt. 33-33.
  • Show author(s) (2018). Alkoholassosiert dysbiose? NGF-nytt. 29-29.
  • Show author(s) (2017). Tarmens viktige mikrober. Del III: Kan avføring brukes som behandling mot sykdommer? Forskning.no.
  • Show author(s) (2017). Tarmens viktige mikrober. Del II: Disse sykdommene kan kobles til det som bor i tarmen. Forskning.no.
  • Show author(s) (2017). Tarmens viktige mikrober. Del I: Tarmens viktige mikrober har stor betydning for helsen. Forskning.no.
  • Show author(s) (2017). Magemål. NGF-nytt. 47-47.
  • Show author(s) (2017). Is i magen. NGF-nytt. 27-27.
  • Show author(s) (2017). Holbergs Hofmesterinde. NGF-nytt. 58-58.
  • Show author(s) (2016). Sauerkraut - mat, medisin og konserveringsmiddel i over 2000 år. NGF-nytt. 46-47.
  • Show author(s) (2016). Melkesyrebakterier - gjøkunger i tarmen? NGF-nytt. 51-54.
  • Show author(s) (2016). Diagnostikk av gjæringsdyspepsi - før og nå. NGF-nytt. 36-37.
  • Show author(s) (2015). Hedonisk hunger, fedme og bearbeidet mat. NGF-nytt. 64-66.
  • Show author(s) (2015). Forstyrrelser i tarmkanalens redoks-biologi - en oversett sykdomsmekanisme? NGF-nytt. 32-36.
  • Show author(s) (2015). Fordøyelse til besvær. Utposten. 18-23.
  • Show author(s) (2015). En mage av stein. NGF-nytt. 43-43.
  • Show author(s) (2014). Tryptofan: "essensiell" også i IBS-patogenesen? NGF-nytt. 12-14.
  • Show author(s) (2014). Skal FODMAP-dietten tilpasses den enkelte pasient? Fordøyelsen. 28-30.
  • Show author(s) (2014). Skal FODMAP-dietten tilpasses den enkelte pasient? NGF-nytt. 20-21.
  • Show author(s) (2014). Pasienter med irritabel tarm: Meld dere inn i Landsforeningen mot fordøyelsessykdommer! Fordøyelsen. 26-26.
  • Show author(s) (2014). Komorbiditet ved opplevd matintoleranse. BestPractice Gastroenterologi. 7-9.
  • Show author(s) (2014). Indol - duften av et sunt indre jordsmonn. NGF-nytt. 36-37.
  • Show author(s) (2013). Immunologi ved uforklart, selvrapportert matoverfølsomhet. Indremedisineren. 40-41.
  • Show author(s) (2013). Guanylat syklase C-stimulering - endelig noe som hjelper mot irritabel tarm? NGF-nytt. 33-33.
  • Show author(s) (2013). Flymage. NGF-nytt. 28-28.
  • Show author(s) (2013). "Lekk tarm": Fleip eller fakta? NGF-nytt. 32-34.
  • Show author(s) (2012). Laktuloseprovokasjon: Nyttig undersøkelse ved irritabel tarm-syndrom? NGF-nytt. 13-14.
  • Show author(s) (2012). Det er ikke allergi alt som romler! Men hva er det da? Helserådet. 17-18.
  • Show author(s) (2012). "MikrObesitas" - og dens mulige behandling med havregrynsgrøt og kanel. NGF-nytt. 10-12.

More information in national current research information system (CRIStin)